COMMUNIQUÉS West-GlobeNewswire

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
04/11/2025
Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPs SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company [...]
CVRx to Present at the Jefferies Global Healthcare Conference in London
04/11/2025
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025
04/11/2025
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American [...]
Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights
04/11/2025
— Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7% — Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth — First nine months revenue of $ [...]
Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year
04/11/2025
C ompany Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and [...]
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
04/11/2025
MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing [...]
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
04/11/2025
Study results further differentiate sotagliflozin from SGLT inhibitors and cardiac myosin inhibitors THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced [...]
Equillium to Participate in Upcoming Investor Conferences
04/11/2025
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe [...]
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
04/11/2025
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other [...]
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
04/11/2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will [...]
Coloplast Finance B.V. - Annual Report, 2024/25
04/11/2025
Hereby please find the Annual Report 2024/25 for the group of Coloplast A/S. Attachment 11_2025_Annual_Report_2024-25
Bionet Launches O’Pet Curv: A New Standard in Veterinary Wireless Monitoring
04/11/2025
TUSTIN, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bionet America, Inc ., a leader in veterinary medical devices, has introduced the new O’Pet Curv, a compact, cloud-connected wireless monitoring system that allows [...]
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
04/11/2025
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
BridgeBio to Participate in November Investor Conferences
04/11/2025
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that [...]
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
04/11/2025
WAYNE, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients [...]
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
04/11/2025
SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate cancer) [...]
Bioventus Reports Third Quarter Financial Results
04/11/2025
Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8% Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per [...]
Repligen Corporation to Present at Upcoming November Conferences
04/11/2025
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming [...]
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
04/11/2025
NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the [...]

Pages